RxDoctor Payments Data

Ankila Chandran, DO

Psychiatry · Cherry Hill, NJNPI 1093781114

Payments from drug & device makers

$2,580in general payments, 2019–2025

Across 79 payments — averaging $32.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$571
  • AbbVie$487
  • Alkermes, Inc.$395
  • Sunovion Pharmaceuticals Inc.$219
  • Teva Pharmaceuticals USA, Inc.$196
  • Axsome Therapeutics, Inc.$125
  • plus $587 from 12 others

What the payments were for

  • Food & beverage$2,52998%
  • Education$512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,580 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$16,187
Medicare patients
35
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FanaptIloperidone11$25,612
Aripiprazole25$2,477
Hydroxyzine Hcl61$1,510
Lurasidone Hcl11$1,493
Bupropion XlBupropion Hcl24$1,198
Quetiapine Fumarate37$1,038
Buspirone Hcl46$914
Carbamazepine ErCarbamazepine17$889
Duloxetine Hcl42$772
Escitalopram Oxalate27$392
Venlafaxine Hcl ErVenlafaxine Hcl37$350
Trazodone Hcl47$347
Benztropine Mesylate24$340
Lamotrigine22$319
Sertraline Hcl34$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Fanapt$30$25,61211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →